GROWTH OF MALIGNANT MELANOMA has occasionally been shown to be hormonedependent. Bodenham & Hale (1972) administered 32p to patients with metastases of malignant melanoma and measured the uptake in the metastases and in control tissues with a Geiger probe. After a few days, when the uptake curve was found to be constant, oestrogens were administered. A change in the uptake curve was found in 4/26 cases. Two of these 4 patients were hypophysectomized and showed remissions for at least 9 months. The 2 others showed regression after administration of either testosterone phenylpropionate in a man and ethinyl oestradiol in a woman. In another report on 5 patients, a melanoma developed or became worse after oestrogen administration (Sadoff et al., 1973) . In a preliminary study regression was reported in 5/44 melanoma patients after treatment with the anti-oestrogenic progestational drug 6a -methylpregn -4 -ene -3,11,20 -trione (NSC-1 7256; Johnson et al., 1966) . Several authors have reported the influence of pregnancy on the course of melanoma. References can be found in the paper of Shiu et al. ( 1976) who showed in their study that with Stage II but not with Stage I melanoma patients the rate of survival for 5 years free of disease was significantly lower in patients who were treated during pregnancy or who had symptoms of activation of the skin lesion during a previous pregnancy, than in those who were nulliparous or who had no symptoms of activationi during a previous pregnancy. In contrast to an adverse effect of pregnancy stands the remarkable case of a patient whose melanoma regressed during successive pregnancies (Boyd, 1957) . Recently Shaw et al. (1978) concluded from a study on a large series of patients that there may be endocrine influences on the rate of formation of metastases and the anatomical distribution of the sites of primary lesions.
Although hormonal dependency of the growth rate of metastases has clearly been shown, it occurs in so few patients that hormonal treatment of melanoma patients with advanced disease, as is practised in mammary carcinoma, is not customary. However, endocrine therapy would become the treatment of choice if it were possible to select appropriate patients by some criterion for hormone dependency. This situation is possible in breast-cancer patients where specific binding of oestrogens to receptor in tumour extract has been shown to correlate with successful hormonal treatment (McCuire et al., 1975 The estimated amount of serum proteins in the cytosol was calculated by multiplying the albumin concentration by a factor of 10/6 (assuming an albumin concentration of 60% in the extracellular protein contaminants of the extracts). The amount of soluble tissue proteins is then the total protein amount minus the amount of serum proteins. Oestrogen and androgen receptors were determined in the extract using agar electrophoresis. This technique has been described in detail by Wagner (1972) . The electrophoresis equipment used in our study was an exact replica of the one described in the paper of Wagner. The electrophoresis separates high-affinity receptors from sex-hormone binding to globulin and unbound hormone, since the former migrates to the anode while the sex-hormone binding globulin and unbound hormone are shifted towards the cathode. As a control we used heated cytosol (1 h at 45°C). The difference between the anodal peaks of the unheated and preheated cytosol was used as a measure of high-affinity steroid binding capacity, which was expressed in fmol of receptor bound per mg tissue protein.
Metastatic excisions
E2 and DHT receptors were determined in excised metastases of patients with histologically proven disseminated malignant melanoma. All specimens were frozen within 1 h and stored at -70°C before the extracts were made. Thirty-nine extracts were assayed within 12 days, and 4 within 4 months. All assays were performed simultaneously with extracts of breast cancers.
The Table shows the results of the assays on 21 metastases of 17 male and 22 metastases of 17 female patients. E2 receptor was measurable in 7/31 cutaneous and 1/9 lymphnode metastases, the concentration in this lymphnode metastasis being the lowest of all measurable assays. In the 3 non-skin, non-lymphnode metastases no E2 receptor was detectable. There is no relationship between the sex of the patients and the presence of E2 receptor in a skin metastasis, and no relationship between the presence of detectable E2 and DHT receptor. DHT-binding activity was found in 7/31 cutaneous, 4/9 lymphnode metastases, and 0/3 non-skin, nonlymphnode metastases. In one patient there was DHT activity found in a skin and a lymphnode metastasis excised at the same time. In 6 patients both assays were performed on another metastasis at another time. In 3 cases the first but not the second, and in 2 cases the second but not the first had detectable E2 receptors. In 2 cases DHT receptor was detectable, one the first and one the second time. Thus, in no case was a receptor detectable on both occasions.
The 2 women with the highest receptor activity (one with E2, the other with DHT) had never been pregnant, nor had they used oral contraceptives. Nearly all patients in whom receptor activity was found had progressive disease; only one man (76/1909) with DHT binding activity in a removed regional lymphnode metastasis, is still disease-free 3 years later. No relationship was found between the presence of receptor and the prognosis of the disease or the age or sex of the patient.
In the 4 instances in which the specimens had to be stored for 4 months, there were 2 cases where E2 receptor was detectable (1.1 and 11 -6 fmol/mg). 
female patient having E2 receptor on at least one occasion in a skin metastasis. Although detectable in 20-25% of the patients the levels are generally too low to be considered of any relevance to endocrine treatment. Moreover, in 6 cases (2 males and 4 females) there was no consistently detectable receptor present, while in none of them was receptor present on 2 occasions. The incidence of E2 positivity in our study is lower than reported by Fisher et al. (1976) who found 16/35 patients with levels higher than 5 fmol/mg cytosol. Another difference from their findings concerns the relationship with the sites of the metastases. While we found E2 receptors virtually only in skin (7/31) and hardly in lymphnode metastases (1/9), Fisher et al. ( 1976) found a prevalence for lymphnode metastases (9/18 of lymph node and 4/12 of skin metastases). In their study, however, a different technique, including the reagent dithiothreitol (DTT) and analysis of the results by Scatchard plot was used. DTT has been suggested to increase the yield of the receptor assay (McGuire & DeLaGarza, 1973; Ratajczak & Hahnel, 1976) , but other laboratories (Mester et al., 1970; Braunsberg, 1975; Keightley et al., 1978) including ours (unpublished results) have found that this reagent is not effective. The analysis by Scatchard plot may lead to erroneous results in the assay of cytosols where the contamination with plasma-binding proteins of lower specificity may be considerable. A critical discussion of this problem from which misclassification of receptors or miscalculation of the dissociation constant (KD) may result, is given by Braunsberg (1975) . For the present discussion we would remark that in the quoted study of Fisher et al. (1976) a constant (KD) as high as 4*9 x 10-9M was calculated, which was considered to represent high-affinity binding. Such a high value, however, may, according to Braunsberg (1975) and others (vide McGuire et al., 1975) rather suggest a low-affinity binding. This could then explain the higher incidence of E2 receptors in melanoma in the study of Fisher et al. (1976) when compared to our virtually negative results. In our study no KD values could be determined, since the technique used is based on incubation with a single saturating oestradiol concentration. There are, however, several arguments that sex-hormone-binding globulin did not interfere in our assay for the receptors. The electrophoresis technique is the only procedure currently available which'separates distinctly specific receptor proteins and sex-hormone-binding globulins, in fact the method allows the separate determination of sex-hormone-binding globulin (Wagner & Rtiffert, 1974) . Our electrophoretic diagrams obtained with the Wagner technique conformed to those published by various investigators (Wagner, 1972; Krieg et al., 1974; Wagner & Jungblut, 1976a,b; Trams & Maass, 1977) . Moreover, the correlation between the results obtained with the electrophoretic method and the charcoal method for oestrogen receptor is excellent (Korsten & Persijn, 1977) .
In 11 cases there was measurable DHTbinding activity. The higher levels above 5 fmol/mg tissue cytosol were found in 4 men and one woman, the latter having the highest level. Also DHT binding activity was not related to the state of the disease, nor to the age and sex of the patients. Two young male patients with advanced disease received anti-testosterone treatment, and one also received ethinyl oestradiol in high doses. However, these treatments had no effect on the progression of the disease. The dose of the antiandrogens may have been too low or the treatment too short, but it may also be that the fraction of melanoma cells without receptor was too large, and it may also be that proliferation of the cells in spite of the presence of a receptor does not require the stimulus of the appropriate hormones. Recently also, Fisher et al. (1978) showed that the presence of £2 receptor did not correlate with the response on the administration of diethylstilboestrol, which occurred only in 2 patients, both having no E2-binding activity, while 4/18 patients with E2 receptor in metastases did not respond.
It can therefore tentatively be concluded that receptor determinations are of no help in the management of patients with advanced malignant melanoma.
